SYNergy between PCI with TAXUS™ and Cardiac Surgery
(SYNTAX Trial)


Sponsor: Boston Scientific

Investigators:
Michael Mack, MD*
Todd Dewey, MD
J. Edward Rosenthal, MD
Mitchell Magee, MD
David Brown, MD*
Taysir Jarrah, MD
Eric Eichhorn, MD
James Edgerton, MD
Tina Worley, RN

Designated Site: Medical City Dallas


The overall study goal is to assess the optimum revascularization treatment for patients with de novo 3vessel coronary artery disease or left main disease by randomizing patients to either PCI with TAXUS stents or CABG. In addition, the CABG registry data could be used to define the population where TAXUS stenting is considered unsuitable for treatment of complex, high risk subsets. Conversely, the PCI registry data using any interventional techniques or devices with or without the use of drug-eluting stents establishes the patients where CABG is considered inappropriate.

* denotes Principal Investigator